Targeting USP33 in multiple sclerosis.
This project started with a disease question: what molecular signals could help explain demyelination in MS, and could one of those signals become a therapeutic target? I followed the gene-expression signal through pathway analysis to an RNAi hypothesis.
I found USP33 through a broader gene-expression screen.
I used GEO2R on brain-tissue samples from 10 controls and 40 MS patients. I filtered genes by statistical significance and fold-change, then used pathway and network tools to interpret the results.
USP33
Selected focal gene because it was significantly overexpressed and connected to ubiquitin-mediated proteolysis.
I wanted to understand how protein regulation might contribute to demyelination.
Multiple sclerosis damages the myelin sheath around neurons. I investigated a possible connection between that clinical phenotype and a molecular path: USP33 overexpression, ubiquitin-mediated proteolysis, and potential degradation of myelin-related proteins such as MBP and PLPs.
USP33 is overexpressed in MS samples.
The MS brain-tissue analysis showed USP33 with p = 1.49E-08 and logFC = 0.97364. The hypothesis is that dysregulated deubiquitination contributes to immune activation and demyelination.
Could reducing USP33 expression change the biology?
After identifying USP33, I asked whether we could downregulate its expression. The poster moves through UCSC, ENCODE, JASPAR, and miRBase to connect gene location, regulatory structure, and RNAi feasibility.
miRBase
The miRNA/siRNA search supported the RNAi idea: use targeted RNA interference to reduce USP33 expression at the mRNA level.
I have a hypothesis to test, with limits the computational analysis cannot resolve.
What worked
I connected a significantly dysregulated gene to a pathway relevant to protein degradation. KEGG identified ubiquitin-mediated proteolysis with FDR 2.61E-06, and STRING-DB added network context around USP33.
What to be careful about
The sample classes were imbalanced: 10 controls versus 40 MS samples. I treat the USP33 signal as a hypothesis that needs validation. The analysis does not establish that reducing its expression would treat MS.
Next experiments
I would next test whether reducing USP33 changes MS-relevant biology. The poster points toward cDNA synthesis, IHC on MS brain samples, and drug-screening assays as the bridge from bioinformatics signal to experimental evidence.